Lejoyeux M
Department of Psychiatry, Groupe Hospitalier Bichat Claude Bernard, Paris, France.
Alcohol Alcohol Suppl. 1996 Mar;31(1):69-75.
Animal studies have shown that alcohol consumption is reduced when serotonin (5-hydroxytryptamine, 5-HT) levels are increased in the central nervous system. Similarly, studies of alcohol-dependent human subjects have shown that treatment with 5-HT reuptake inhibitors (i.e. zimeldine, citalopram, fluoxetine, and fluvoxamine) decreases the desire to drink alcohol and improves symptoms of alcohol-related anxiety and depression in patients who have undergone detoxification. However, not all studies have shown them to be an effective treatment to help maintain recovery in alcohol dependence. The exact mechanisms of action of the 5-HT reuptake inhibitors are not yet fully understood and additional studies are needed. However, at this time, the 5-HT reuptake inhibitors may be effective pharmacotherapies for alcohol-related depression.
动物研究表明，当血清素（5-羟色胺，5-HT）在中枢神经系统中的水平升高时，酒精摄入量会减少。同样，对酒精依赖的人类受试者的研究表明，使用5-羟色胺再摄取抑制剂（即齐美利定、西酞普兰、氟西汀和氟伏沙明）进行治疗，可降低戒酒者饮酒的欲望，并改善与酒精相关的焦虑和抑郁症状。然而，并非所有研究都表明它们是有助于维持酒精依赖康复的有效治疗方法。5-羟色胺再摄取抑制剂的确切作用机制尚未完全了解，还需要进一步研究。不过，目前5-羟色胺再摄取抑制剂可能是治疗与酒精相关抑郁症的有效药物疗法。
